Marca H M Wauben Selected Research

Ligands

2/2005	Possibilities and limitations in the rational design of modified peptides for T cell mediated immunotherapy.
7/2002	Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marca H M Wauben Research Topics

Disease

10	Experimental Arthritis 09/2011 - 01/2002
7	Arthritis (Polyarthritis) 09/2011 - 01/2002
5	Inflammation (Inflammations) 01/2018 - 03/2002
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 02/2005 - 01/2002
3	Neoplasms (Cancer) 01/2022 - 10/2018
3	Joint Diseases (Joint Disease) 01/2018 - 01/2016
3	Autoimmune Diseases (Autoimmune Disease) 02/2005 - 01/2002
2	Rheumatoid Arthritis 01/2005 - 04/2004
1	Virus Diseases (Viral Diseases) 01/2019
1	Myocardial Infarction 01/2016
1	Ischemia 01/2016
1	Liver Diseases (Liver Disease) 10/2014
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2006
1	Multiple Sclerosis 08/2003
1	Necrosis 08/2003
1	Asthma (Bronchial Asthma) 08/2002
1	Eosinophilia 08/2002
1	Disease Progression 01/2002

Drug/Important Bio-Agent (IBA)

7	Liposomes (Liposome)IBA 09/2011 - 01/2002
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2002
6	Peptides (Polypeptides)IBA 02/2005 - 01/2002
5	AntigensIBA 10/2018 - 07/2002
4	EpitopesIBA 01/2006 - 05/2002
3	GlucocorticoidsIBA 09/2011 - 01/2002
3	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 04/2006 - 07/2003
2	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2016
2	Pharmaceutical PreparationsIBA 09/2011 - 01/2005
2	IntegrinsIBA 04/2006 - 01/2002
2	LigandsIBA 02/2005 - 07/2002
2	Matrix Metalloproteinases (MMPs)IBA 04/2004 - 01/2002
2	prednisolone phosphate FDA LinkGeneric 11/2003 - 07/2003
1	Membrane LipidsIBA 01/2019
1	EnzymesIBA 10/2014
1	EstersIBA 09/2011
1	Phosphates (Orthophosphate)IBA 09/2011
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 09/2011
1	dexamethasone 21-phosphate FDA LinkGeneric 04/2006
1	arginyl-glycyl-aspartic acidIBA 04/2006
1	LipopolysaccharidesIBA 04/2006
1	Aggrecans (Aggrecan)IBA 01/2006
1	FibrillinsIBA 01/2006
1	Peptide TIBA 02/2005
1	Monoclonal AntibodiesIBA 01/2005
1	Myelin Basic ProteinIBA 02/2004
1	Amino Acids FDA Link 02/2004
1	CholesterolIBA 11/2003
1	PolymersIBA 11/2003
1	poly(2-hydroxyethyl acrylate) (PHEA)IBA 11/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2003
1	Hormones (Hormone)IBA 08/2003
1	Prednisolone (Predate)FDA LinkGeneric 08/2003
1	InterleukinsIBA 08/2002
1	Interleukin-5 (Interleukin 5)IBA 08/2002
1	Methacholine Chloride (Methacholine)FDA Link 08/2002
1	AllergensIBA 08/2002
1	CytokinesIBA 07/2002
1	Chaperonin 60IBA 07/2002
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 07/2002
1	AntibodiesIBA 07/2002
1	Interleukin-4 (Interleukin 4)IBA 07/2002
1	Transforming Growth Factor beta (TGF-beta)IBA 07/2002
1	Interleukin-10 (Interleukin 10)IBA 07/2002
1	incomplete Freund's adjuvantIBA 05/2002
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 03/2002
1	Integrin alpha4IBA 01/2002
1	Integrin alpha4beta1 (VLA-4)IBA 01/2002

Therapy/Procedure

4	Therapeutics 01/2018 - 07/2003
2	Immunotherapy 04/2004 - 01/2002
1	Injections 07/2003
1	Intravenous Administration 07/2003
1	Aftercare (After-Treatment) 07/2003
1	Intranasal Administration 07/2002